Cost Minimization Analysis of Herceptin Subcutaneous versus Herceptin intravenous treatment for patients with HER2+ Breast Cancer in Greece

Conclusion Whilst drug costs are even, from an economic perspective treatment with Herceptin-SC is associated with a lower economic burden in comparison to Herceptin-IV in the management of patients with HER2+ EBC and MBC. Hence, the substitution of Herceptin-IV with Herceptin-SC can produce valuable savings for the Greek health care system, especially in the current economic environment where resources are scarce.
Source: Journal of Cancer Policy - Category: Cancer & Oncology Source Type: research